Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
-
Market Cap
10.26B
Enterprise Value
13.48B
Income
337.20M
Sales
6.64B
Book/sh
8.61
Cash/sh
0.69
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13500
IPO
May 17, 2019
P/E
30.52
Forward P/E
17.04
PEG
6.58
P/S
1.55
P/B
1.76
P/C
22.10
P/FCF
23.36
EV/EBITDA
13.93
EV/Sales
2.03
Quick Ratio
1.27
Current Ratio
1.89
Debt/Eq
0.63
LT Debt/Eq
0.63
Option/Short
Yes / Yes
EPS (ttm)
0.50
EPS next Y
0.89
EPS next Q
0.22
EPS this Y
-9.22%
EPS next Y
8.77%
EPS next 5Y
2.59%
EPS past 3/5Y
- -
Sales past 3/5Y
-4.46% 0.49%
EPS Y/Y TTM
517.17%
Sales Y/Y TTM
0.92%
EPS Q/Q
128.61%
Sales Q/Q
4.59%
Insider Own
3.07%
Insider Trans
0.05%
Inst Own
102.93%
Inst Trans
2.06%
ROA
2.89%
ROE
5.91%
ROIC
3.56%
Gross Margin
30.45%
Oper. Margin
8.27%
Profit Margin
5.08%
SMA20
-6.93%
SMA50
-2.81%
SMA200
34.42%
Trades
Shs Outstand
677.70M
Shs Float
656.81M
52W High
17.45 -13.24%
52W Low
7.26 108.40%
Volatility
4.20% 3.28%
ATR (14)
0.55
RSI (14)
37.63
Beta
0.95
Rel Volume
0.00
Avg Volume
8.66M
Volume
0
Perf Week
-9.23%
Perf Month
-1.37%
Perf Quarter
11.41%
Perf Half Y
82.19%
Perf YTD
32.11%
Perf Year
30.74%
Perf 3Y
-17.58%
Perf 5Y
-60.35%
Perf 10Y
-
Prev Close
15.14
Price
15.14
Change %
0.00%
Consensus
Hold
Avg. Price Target
$17.35
Implied Upside
+14.6%
Analysts16incl. previous ratings
Rating Distribution1 Buy · 13 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 09, 2026Initiated
UBS logoUUBS
Neutral$16+5.7%
Jul 29, 2026Upgrade
JEF logoJJefferies
Underperform → Hold$13-14.1%
Jun 26, 2026Resumed
BBernstein
Mkt Perform$10.50-30.6%
Jun 02, 2026Resumed
WWolfe Research
Underperform$7-53.8%
May 15, 2026Resumed
RY logoRRBC Capital Mkts
Sector Perform$9-40.6%
Mar 06, 2026Downgrade
BCS logoBBarclays
Equal Weight → Underweight$8.50-43.9%
Jan 05, 2026Downgrade
EVR logoEEvercore ISI
Outperform → In-line$12-20.7%
Dec 17, 2025Downgrade
JEF logoJJefferies
Hold → Underperform$9-40.6%
Dec 15, 2025Downgrade
BAC logoBBofA Securities
Buy → Neutral$13-14.1%
Nov 04, 2025Downgrade
RJF logoRRaymond James
Outperform → Mkt Perform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LUCIER GREGORY TDirectorMay 08 '26Buy8.3210,00083,20060,000May 11 04:39 PM
Dingemans SimonDirectorMay 01 '26Buy8.1425,000203,50025,000May 05 07:44 PM
MEHRA SANJEEV KDirectorMar 10 '26Buy8.01125,0001,001,250475,000Mar 11 05:10 PM
LUCIER GREGORY TDirectorFeb 19 '26Buy9.1650,000458,00050,000Feb 23 08:53 PM
SUMME GREGORY LDirectorFeb 12 '26Buy9.40100,000940,000400,000Feb 12 05:24 PM
MEHRA SANJEEV KDirectorDec 05 '25Buy11.09350,0003,881,500350,000Dec 09 05:11 PM
Ligner EmmanuelPresident and CEONov 17 '25Buy11.3587,500993,125283,424Nov 17 05:45 PM
Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. Its portfolio includes biopharma, healthcare, education and government, as well as advanced technologies and applied materials industries. It sells materials, equipment, instrumentation, and offers specialty procurement. The company operates through the Laboratory Solutions segment and Bioscience Production. The Laboratory Solutions segment focuses on research, diagnostic, and quality control workflows. The Bioscience Production segment focuses on high-purity materials for bioprocessing and medical technologies. Avantor was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
PresidentMr. Emmanuel Ligner
Executive VPMr. Claudius O. Sokenu
President of Laboratory SolutionsMr. Corey D. Walker
Executive Vice President of Bioscience ProductionMr. Benoit Gourdier
Executive VP & CFOMr. Todd W. Garner CPA